Evidence of a thyrotropin-releasing activity of ovine corticotropin-releasing factor in the domestic fowl (Gallus domesticus).
Ovine corticotropin-releasing factor (oCRF) administered to 19-day-old chicken embryos (E19) increased plasma concentration of pituitary glycoprotein alpha-subunit concentrations within 15 min for at least 4 hr. Follicle stimulating hormone levels were unchanged, while plasma luteinizing hormone concentrations only began to increase 1 hr after the oCRF treatment. Calculation of circulating thyrotropin (TSH) indicator values revealed a rapid elevation in TSH plasma levels following oCRF. Concentrations of thyroxine (T4), 3,5,3'-triiodothyronine (T3), 3,3',5'-triiodothyronine (rT3), and corticosterone increased from 1 hr postinjection. Hypothalamic outer ring deiodinating type II increased and hepatic inner ring deiodinating type III fell after 2 and 4 hr, explaining at least in part the plasma T3 increase at the end of the experiment. In a second experiment, using E18 chicks, a comparison was made between the effects of a single injection of 2 micrograms oCRF and 20 mlU bovine TSH. Both hormones increased T4, T3, and rT3 plasma concentrations, supporting the hypothesis of a TSH-releasing activity for oCRF in the embryonic chicken. The proposed TSH-mediated effect of CRF on thyroid function was further confirmed in two in vitro experiments in which oCRF did not directly influence the thyroidal T4 secretion but, when applied to pituitaries, clearly increased the alpha-subunit release. In chickens CRF is concluded to not only control the adrenal axis, but also to participate in the coordination of avian TSH release.
Geris
K L
KL
Laboratory of Comparative Endocrinology, K.U. Leuven, Louvain, Belgium. kris.geris@bio.kuleuven.ac.be
Kotanen
S P
SP
Berghman
L R
LR
Kühn
E R
ER
Darras
V M
VM
D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage; D000818:Animals; D002417:Cattle; D002642:Chick Embryo; D002645:Chickens; D003346:Corticotropin-Releasing Hormone / Q000008:administration & dosage / Q000494:pharmacology*; D015292:Glycoprotein Hormones, alpha Subunit / Q000097:blood / Q000378:metabolism; D007275:Injections, Intravenous; D007453:Iodide Peroxidase / Q000187:drug effects / Q000378:metabolism*; D007986:Luteinizing Hormone / Q000097:blood / Q000187:drug effects / Q000378:metabolism; D008297:Male; D010908:Pituitary Hormones, Anterior / Q000097:blood* / Q000378:metabolism; D012756:Sheep; D013963:Thyroid Hormones / Q000097:blood* / Q000378:metabolism; D013972:Thyrotropin / Q000097:blood* / Q000187:drug effects / Q000378:metabolism; D013974:Thyroxine / Q000097:blood / Q000187:drug effects / Q000378:metabolism; D013997:Time Factors; D014018:Tissue Distribution; D014284:Triiodothyronine / Q000097:blood / Q000187:drug effects / Q000378:metabolism
D015292:Glycoprotein Hormones, alpha Subunit; D010908:Pituitary Hormones, Anterior; D013963:Thyroid Hormones; D014284:Triiodothyronine; D000324:Adrenocorticotropic Hormone; D007986:Luteinizing Hormone; D013972:Thyrotropin; D003346:Corticotropin-Releasing Hormone; D007453:Iodide Peroxidase; D013974:Thyroxine